In the swirling world of technological innovation, Artificial Intelligence has carved out a distinctive niche. It’s causing ripples of change across multiple sectors, but perhaps none more so than healthcare.
Poolbeg Pharma (LON:POLB, OTCQB: POLBF), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, announces that further to its announcement on 19 September 2023, the oral opposition hearing scheduled by the
Bringing a new drug to market is an enormously complex and expensive process, often taking over a decade and costing upwards of $2 billion. The pharmaceutical industry faces increasing pressure
Dublin-based infectious disease specialist Poolbeg Pharma has received a green light from Japan’s patent office, relating to a patent application for the company’s “potential blockbuster treatment” for severe influenza. The
Roundtable discussion featuring Artificial Intelligence hot topics, such as: The future of AI How AI could have contributed to the COVID-19 pandemic Highlights from the exciting collaboration between Poolbeg Pharma
Poolbeg Pharma Plc (LON:POLB, OTCQB: POLBF), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, has announced that it has received a notice of allowance from the Japanese Patent Office in
Hosted by DDW and co-sponsored by Benchling and Proscia, “AI and Lab Automation: What are the key benefits and latest innovations?” will be free to attend on 10 October at 7AM PDT
Poolbeg Pharma (LON:POLB, OTCQB: POLBF), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, has announced that the opposition to one of its European patents (Immunomodulator I) that was previously
Initial data from the CPHI Annual Report 2023, which provides insight from 250 global pharmaceutical companies, reveals that AI (artificial intelligence) is expected to transform every area of the industry,
Poolbeg Pharma plc (LON:POLB, OTCQB: POLBF), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, has announced its unaudited interim results for the six months to 30 June 2023.
© 2025 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
